Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959448 | 0.89 | MAPK14 (0.65) | MAPK14MAPK11TRPA1 | |
| SCHEMBL3965119 | 0.87 | MAPK14 (0.67) | MAPK14MAPK11TRPA1 | |
| SCHEMBL3964339 | 0.87 | MAPK14 (0.67) | MAPK14MAPK11TRPA1 | |
| SCHEMBL5093596 | 0.84 | MAPK14 (0.64) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4014028 | 0.84 | MAPK14 (0.72) | MAPK14MAPK11TRPA1 | |
| SCHEMBL14566802 | 0.82 | MAPK14 (0.70) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4015558 | 0.82 | MAPK14 (0.70) | MAPK14MAPK11TRPA1 | |
| SCHEMBL3820480 | 0.82 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL4013948 | 0.81 | MAPK14 (0.68) | MAPK14MAPK11TRPA1 | |
| SCHEMBL3864408 | 0.81 | MAPK14 (0.68) | MAPK14MAPK11TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091952-A1 | PYRAZOLO Ý3, 4 -D¨PYRIMIDINE P38 MAP KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-7563800-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563800-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563800-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2008074676-A1 | PYRAZOLO [3, 4 -D] PYRIMIDINE P38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074676-A1 | PYRAZOLO [3, 4 -D] PYRIMIDINE P38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAPK14 33/4885MAPK11 39/4885TRPA1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.